巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Spero Therapeutics

SPRO
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Spero Therapeutics - 延遲價格・最後更新於 23/01 22:00
最高位
--
最低位
--
開市價
--
前收市價
11.620
成交量(千)
--
成交額(百萬)
--
買入
--
賣出
--
每手股數
--
市值(百萬)
375.60
市盈率
--
息率
--
差價
--
52週高低
22.235 - 11.570
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Spero Therapeutics
證券代碼
SPRO.US
所屬板塊
Biotechnology
公司業務
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
發行量
29504257
公司總部
675 Massachusetts Avenue, 14th Floor
公司網址
https://www.sperotherapeutics.com
公司電郵
IR@sperotherapeutics.com
公司電話
+1 857 242-1600
暫無內容

關於

Spero Therapeutics(SPRO.US)所屬的行業板塊為Biotechnology。
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
詳細公司背景可參考: https://www.sperotherapeutics.com